University Center for Gastrointestinal and Liver Diseases, Clarunis, University of Basel, Basel, Switzerland.
Institute of Pathology and Medical Genetics, University Hospital Basel, Basel, Switzerland.
Sci Rep. 2021 Jan 12;11(1):775. doi: 10.1038/s41598-020-80382-2.
Since colorectal cancer (CRC) remains one of the most common malignancies, a tremendous amount of studies keep taking place in this field. Over the past 25 years, a notable part of the scientific community has focused on the association between the immune system and colorectal cancer. A variety of studies have shown that high densities of infiltrating CD8+ T-cells are associated with improved disease-free and overall survival in CRC. Stromal cell-derived factor-1 (SDF-1) is a protein that regulates leukocyte trafficking and is variably expressed in several healthy and malignant tissues. There is strong evidence that SDF-1 has a negative prognostic impact on a variety of solid tumors. However, the existing data do not provide sufficient evidence that the expression of SDF-1 has an influence on CRC. Knowing nowadays, that the microenvironment plays a crucial role in the development of cancer, we hypothesized that the expression of SDF-1 in CRC could influence the prognostic significance of CD8+ T-cells, as an indicator of the essential role of the immune microenvironment in cancer development. Therefore, we explored the combined prognostic significance of CD8+ T-cell density and SDF-1 expression in a large CRC collective. We analyzed a tissue microarray of 613 patient specimens of primary CRCs by immunohistochemistry (IHC) for the CD8 + T-cells density and the expression of SDF-1 by tumor cells and tumor-infiltrating immune cells. Besides, we analyzed the expression of SDF-1 at the RNA level in The Cancer Genome Atlas cohort. We found that the combined high CD8+ T-cell infiltration and expression of SDF-1 shows a favorable 5-year overall survival rate (66%; 95% CI 48-79%) compared to tumors showing a high expression of CD8+ T-cell only (55%; 95% CI 45-64%; p = 0.0004). After stratifying the patients in nodal negative and positive groups, we found that the prognostic significance of CD8+ T-cell density in nodal positive colorectal cancer depends on SDF-1 expression. Univariate and multivariate Hazard Cox regression survival analysis considering the combination of both markers revealed that the combined high expression of SDF-1 and CD8+ T-cell density was an independent, favorable, prognostic marker for overall survival (HR = 0.34, 95% CI 0.17-0.66; p = 0.002 and HR = 0.45, 95% CI 0.23-0.89; p = 0.021, respectively). In our cohort there was a very weak correlation between SDF-1 and CD8+ T-cells (r = 0.13, p = 0.002) and in the trascriptomic expression of these two immune markers display a weak correlation (r = 0.28, p < 0.001) which was significantly more pronounced in stage III cancers (r = 0.40, p < 0.001). The combination of high CD8+ T-cell density and expression of SDF-1 represents an independent, favorable, prognostic condition in CRC, mostly in patients with stage III disease.
由于结直肠癌(CRC)仍然是最常见的恶性肿瘤之一,因此该领域仍有大量研究在进行。在过去的 25 年中,科学界的相当一部分人一直专注于免疫系统与结直肠癌之间的关联。许多研究表明,浸润性 CD8+T 细胞的高密度与 CRC 无病和总生存的改善有关。基质细胞衍生因子-1(SDF-1)是一种调节白细胞迁移的蛋白质,在几种健康和恶性组织中表达不同。有强有力的证据表明 SDF-1 对多种实体瘤具有负预后影响。然而,现有数据并没有提供足够的证据表明 SDF-1 的表达对 CRC 有影响。如今,我们知道微环境在癌症的发展中起着至关重要的作用,我们假设 SDF-1 在 CRC 中的表达可能会影响 CD8+T 细胞的预后意义,因为这是免疫微环境在癌症发展中起关键作用的一个指标。因此,我们在一个大型 CRC 集合中研究了 CD8+T 细胞密度和 SDF-1 表达的联合预后意义。我们通过免疫组织化学(IHC)分析了 613 例原发性 CRC 患者组织微阵列中 CD8+T 细胞密度和 SDF-1 的表达情况,肿瘤细胞和肿瘤浸润免疫细胞。此外,我们还在 The Cancer Genome Atlas 队列中分析了 SDF-1 的 RNA 水平表达。我们发现,与仅高表达 CD8+T 细胞的肿瘤相比,高浸润 CD8+T 细胞和 SDF-1 表达的组合显示出有利的 5 年总生存率(66%;95%CI 48-79%)(p=0.0004)。在对淋巴结阴性和阳性组患者进行分层后,我们发现 CD8+T 细胞密度在淋巴结阳性结直肠癌中的预后意义取决于 SDF-1 的表达。考虑到两种标志物的组合的单变量和多变量危险 Cox 回归生存分析表明,SDF-1 和 CD8+T 细胞密度的联合高表达是总生存的独立、有利的预后标志物(HR=0.34,95%CI 0.17-0.66;p=0.002 和 HR=0.45,95%CI 0.23-0.89;p=0.021)。在我们的队列中,SDF-1 与 CD8+T 细胞之间的相关性非常弱(r=0.13,p=0.002),这两种免疫标志物的转录组表达也显示出较弱的相关性(r=0.28,p<0.001),在 III 期癌症中这种相关性更为显著(r=0.40,p<0.001)。高 CD8+T 细胞密度与 SDF-1 表达的结合代表了 CRC 的一个独立的、有利的预后条件,主要是在 III 期疾病的患者中。